BR112022000883A2 - Proteína de fusão de um anticorpo eta e de um supressor de tgf-ss, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica e uso de uma composição farmacêutica - Google Patents

Proteína de fusão de um anticorpo eta e de um supressor de tgf-ss, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica e uso de uma composição farmacêutica

Info

Publication number
BR112022000883A2
BR112022000883A2 BR112022000883A BR112022000883A BR112022000883A2 BR 112022000883 A2 BR112022000883 A2 BR 112022000883A2 BR 112022000883 A BR112022000883 A BR 112022000883A BR 112022000883 A BR112022000883 A BR 112022000883A BR 112022000883 A2 BR112022000883 A2 BR 112022000883A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
tgf
suppressor
fusion protein
eta antibody
Prior art date
Application number
BR112022000883A
Other languages
English (en)
Inventor
Cheng Zhang
Chenjiang Yao
Hua Zhang
Shuqian Jing
Xiaofeng Wang
Original Assignee
Gmax Biopharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmax Biopharm Llc filed Critical Gmax Biopharm Llc
Publication of BR112022000883A2 publication Critical patent/BR112022000883A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

proteína de fusão de um anticorpo eta e de um supressor de tgf-ß, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica e uso de uma composição farmacêutica. trata-se de uma proteína de fusão de um anticorpo eta e de um supressor de tgf-ß. também é fornecida uma composição farmacêutica da proteína de fusão do anticorpo eta e do supressor de tgf-ß. é fornecido, ainda, um método para tratar, prevenir ou melhorar um ou mais sintomas de hipertensão arterial pulmonar, hipertensão pulmonar, fibrose pulmonar ou fibrose cardiovascular usando-se a proteína de fusão do anticorpo eta e do supressor de tgf-ß.
BR112022000883A 2019-07-17 2020-07-14 Proteína de fusão de um anticorpo eta e de um supressor de tgf-ss, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica e uso de uma composição farmacêutica BR112022000883A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910645466.XA CN112239507A (zh) 2019-07-17 2019-07-17 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
PCT/CN2020/101857 WO2021008519A1 (zh) 2019-07-17 2020-07-14 ETA抗体与TGF-βTrap的融合蛋白质，以及其药物组合物和应用

Publications (1)

Publication Number Publication Date
BR112022000883A2 true BR112022000883A2 (pt) 2022-03-08

Family

ID=74167347

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000883A BR112022000883A2 (pt) 2019-07-17 2020-07-14 Proteína de fusão de um anticorpo eta e de um supressor de tgf-ss, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica e uso de uma composição farmacêutica

Country Status (11)

Country Link
US (1) US20220265771A1 (pt)
EP (1) EP4008731A4 (pt)
JP (1) JP2022540918A (pt)
KR (1) KR20220035155A (pt)
CN (2) CN112239507A (pt)
AU (1) AU2020313155A1 (pt)
BR (1) BR112022000883A2 (pt)
CA (1) CA3147687A1 (pt)
MX (1) MX2022000452A (pt)
TW (1) TW202108630A (pt)
WO (1) WO2021008519A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN115141276A (zh) * 2021-03-31 2022-10-04 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
CN115490770A (zh) * 2021-06-17 2022-12-20 鸿运华宁（杭州）生物医药有限公司 一种能与人eta和人cd3结合的双特异性抗体及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
JP6170040B2 (ja) * 2011-05-25 2017-07-26 インターミューン， インコーポレイテッド ピルフェニドン及び選択された患者における抗線維化療法
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9750761B2 (en) * 2014-05-21 2017-09-05 University Of Rochester LDH inhibitors as treatment for fibrosis and fibrotic-related disorders
CN105669863B (zh) * 2014-12-05 2019-09-13 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
EP3344660A4 (en) * 2015-08-31 2019-07-03 National Research Council of Canada TGF-BETA-RECEPTOR-EKTODOMÄNENFUSIONSMOLEKÜLE AND USES THEREOF
NZ740686A (en) * 2015-09-18 2021-12-24 Arch Oncology Inc Therapeutic cd47 antibodies
UA125062C2 (uk) * 2015-10-01 2022-01-05 Потенза Терапеутікс, Інк. Анти-tigit антигензв'язуючі білки і способи їх застосування
CN107987162A (zh) * 2016-10-27 2018-05-04 鸿运华宁（杭州）生物医药有限公司 Etar抗体，其药物组合物及其应用
EP3500302A4 (en) * 2016-08-16 2020-03-25 University of Maryland, Baltimore METHOD FOR TREATING CANCER WITH BIFUNCTIONAL MOLECULES TARGETING GROWTH FACTORS

Also Published As

Publication number Publication date
TW202108630A (zh) 2021-03-01
CA3147687A1 (en) 2021-01-21
JP2022540918A (ja) 2022-09-20
EP4008731A4 (en) 2023-07-19
AU2020313155A1 (en) 2022-02-17
MX2022000452A (es) 2022-04-25
WO2021008519A1 (zh) 2021-01-21
KR20220035155A (ko) 2022-03-21
CN112239507A (zh) 2021-01-19
US20220265771A1 (en) 2022-08-25
EP4008731A1 (en) 2022-06-08
CN114127126A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
BR112022000883A2 (pt) Proteína de fusão de um anticorpo eta e de um supressor de tgf-ss, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica e uso de uma composição farmacêutica
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112019005964A2 (pt) proteínas de fusão imunomoduladoras
EA201691111A1 (ru) Химерные белки фактора viii и их применение
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112018072953A2 (pt) polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
EA201891990A1 (ru) Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна
BR112022001359A2 (pt) Método e composição para anticorpos anti-cd73 e variantes
BR112022012439A2 (pt) Anticorpos isolados, ácido nucleico isolado, vetor isolado, célula hospedeira isolada e métodos para produzir um anticorpo que se liga à apol1, para detectar apolipoproteína l1 em uma amostra, para distinguir apolipoproteína l1 endógena, para distinguir as formas g0 e g1 de apolipoproteína l1 da forma apol1 g2 e para detectar especificamente células de podócitos
BR112021021356A2 (pt) Movimento global para candidatos de modo de mesclagem em interprevisão
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112021010241A2 (pt) Construto multigene para expressão de proteínas imunomodulatórias e métodos de uso
BR112021020369A2 (pt) Composições e métodos de uso do seneca valley vírus (svv) para tratamento do câncer
BR112018073889A8 (pt) Aparelho e método para determinar informações de similaridade
EP3594236A4 (en) NAV1.9 TARGET POLYPEPTIDE, COMBINED ANTIBODIES AND ANTIBODY FRAGMENTS AND RELATED PHARMACEUTICAL COMPOSITION
BR112018005464A2 (pt) expressão de proteínas contendo fc
EP3594234A4 (en) NAV1.9 TARGET POLYPEPTIDE, COMBINED ANTIBODIES AND ANTIBODY FRAGMENTS AND RELATED PHARMACEUTICAL COMPOSITION
BR112022010757A2 (pt) Região de anticorpo fc com afinidade de ligação aumentada para fc-gama-riib.
EP4059517A4 (en) NEW SOLUBLE CD14 ANTI-SUBTYPE ANTIBODY AND ITS USE
WO2017109756A3 (es) Péptidos sintéticos moduladores del receptor nmda
MY194322A (en) Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
Changling Research on the Characteristics and Application of Academic Papers Altmetrics Metrics
PL429689A1 (pl) Usprawniona obudowa z ramionami